-
Natrecor: Safety Concerns And Off-Label Investigation Plague Scios And J&J
Medical Journal Articles About Natrecor And Renal Failure May Have Been Cause Of Reduced Natrecor Use In Late 2005 Steve Johnson provides some insights about the so-called "off-label" use of prescription drugs with his…
-
Case Reports: Serious Blood Sugar Problems In Patients Taking Tequin
Article Finds Tequin Is "Probable Cause" of Hyperglycemia And Hypoglycemia, Or Dysglycemia, In Most Of Subject Cases There is a Case Reports article concerning Tequin (gatifloxacin) causing serious blood-sugar problems, or dysglycemia, in the…
-
Health Canada’s MedEffect Now Offers Online Reporting Of Adverse Drug Reactions
Objective Is To Increase Percentage Of ADRs That Get Reported To Regulators In October 2006 Health Canada announced that its MedEffect web site is now able to accept online reports of suspected adverse drug…
-
Adverse Drug Reactions Lead To 700,000 ER Visits Annually
JAMA Article Finds That Older Patients Are Most Likely To Have Such Problems As recently discussed in our four-part series "ADRs in US" — see sidebar, under heading Selected: 2006 — adverse drug reactions…
-
Documentary Film 2006: “Money Talks: Profits Before Patient Safety”
A Closer Look At The Promotion And Sales Tactics Of Big Pharma Industry I recently received an email informing me about writer / director Kathleen Slattery-Moschkau’s independent documentary, Money Talks: Profits Before Patient Safety…
-
Ortho Evra Patch Label Change: Serious Blood Clot Risk Warning Increased
Results From Two Studies Prompt Action By FDA and Johnson & Johnson In September 2006 the FDA and Ortho-McNeil Pharmaceutical — a Johnson & Johnson (J&J) company — announced changes to the Ortho Evra…
